Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Tiberghien AC"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tiberghien AC; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Vijayakrishnan B; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Esfandiari A; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom., Ahmed M; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Pardo R; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Bingham J; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom., Adams L; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Santos K; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Kang GD; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Pugh KM; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Afif-Rider S; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Vashisht K; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Haque K; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Tammali R; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Rosfjord E; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Savoca A; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hartley JA; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom., Howard PW; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 Feb 01; Vol. 22 (2), pp. 254-263.
Autor:
Chen R; Research and Development, AstraZeneca, Gaithersburg, Maryland., Rajan S; Research and Development, AstraZeneca, Gaithersburg, Maryland., Overstreet MG; Research and Development, AstraZeneca, Gaithersburg, Maryland. michael.overstreet@astrazeneca.com., Hurt EM; Research and Development, AstraZeneca, Gaithersburg, Maryland., Thomas SB; Research and Development, AstraZeneca, Gaithersburg, Maryland., Muniz-Medina V; Research and Development, AstraZeneca, Gaithersburg, Maryland., Ward C; Research and Development, AstraZeneca, Gaithersburg, Maryland., Sadowska A; Research and Development, AstraZeneca, Gaithersburg, Maryland., Fleming R; Research and Development, AstraZeneca, Gaithersburg, Maryland., Karanth S; Research and Development, AstraZeneca, Gaithersburg, Maryland., Breen S; Research and Development, AstraZeneca, Gaithersburg, Maryland., Zheng B; Research and Development, AstraZeneca, Gaithersburg, Maryland., Wu Y; Research and Development, AstraZeneca, Gaithersburg, Maryland., Iverson WO; Research and Development, AstraZeneca, Gaithersburg, Maryland., Novick S; Research and Development, AstraZeneca, Gaithersburg, Maryland., O'Day T; Research and Development, AstraZeneca, Gaithersburg, Maryland., Shah DP; Research and Development, AstraZeneca, Gaithersburg, Maryland., Dimasi N; Research and Development, AstraZeneca, Gaithersburg, Maryland., Tiberghien AC; Spirogen, London, United Kingdom., Osbourn J; Research and Development, AstraZeneca, Cambridge, United Kingdom., Walker J; Research and Development, AstraZeneca, Gaithersburg, Maryland.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2020 Aug; Vol. 19 (8), pp. 1649-1659. Date of Electronic Publication: 2020 May 13.
Autor:
Tiberghien AC; Spirogen, QMB Innovation Centre , 42 New Road , E1 2AX London , United Kingdom., Howard PW; Spirogen, QMB Innovation Centre , 42 New Road , E1 2AX London , United Kingdom., Goundry WRF; Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit , AstraZeneca , Macclesfield , United Kingdom., McCormick M; Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit , AstraZeneca , Macclesfield , United Kingdom., Parker JS; Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit , AstraZeneca , Macclesfield , United Kingdom.
Publikováno v:
The Journal of organic chemistry [J Org Chem] 2019 Apr 19; Vol. 84 (8), pp. 4830-4836. Date of Electronic Publication: 2019 Jan 11.
Autor:
Kinneer K; Oncology Research, MedImmune, Gaithersburg, Maryland. kinneerk@medimmune.com., Meekin J; Oncology Research, MedImmune, Gaithersburg, Maryland., Tiberghien AC; Spirogen, QMB Innovation Centre, London, United Kingdom., Tai YT; The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Phipps S; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland., Kiefer CM; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland., Rebelatto MC; Translational Medicine, MedImmune, Gaithersburg, Maryland., Dimasi N; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland., Moriarty A; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Papadopoulos KP; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Sridhar S; Translational Medicine, MedImmune, Gaithersburg, Maryland., Gregson SJ; Spirogen, QMB Innovation Centre, London, United Kingdom., Wick MJ; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Masterson L; Spirogen, QMB Innovation Centre, London, United Kingdom., Anderson KC; The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Herbst R; Oncology Research, MedImmune, Gaithersburg, Maryland., Howard PW; Spirogen, QMB Innovation Centre, London, United Kingdom., Tice DA; Oncology Research, MedImmune, Gaithersburg, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Dec 15; Vol. 24 (24), pp. 6570-6582. Date of Electronic Publication: 2018 Aug 21.
Autor:
Christie RJ; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA. christier@medimmune.com., Tiberghien AC; Spirogen Inc., London, E1 2AX, UK. tiberghiena@medimmune.com., Du Q; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA. duq@medimmune.com., Bezabeh B; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA. bezabehb@medimmune.com., Fleming R; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA. flemingr@medimmune.com., Shannon A; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA. amanda.shannon@marquette.edu., Mao S; Oncology Research, MedImmune, Gaithersburg, MD 20878, USA. maosh@medimmune.com., Breen S; Oncology Research, MedImmune, Gaithersburg, MD 20878, USA. breens@medimmune.com., Zhang J; Oncology Research, MedImmune, Gaithersburg, MD 20878, USA. zhangj@medimmune.com., Zhong H; Oncology Research, MedImmune, Gaithersburg, MD 20878, USA. zhongh@medimmune.com., Harper J; Oncology Research, MedImmune, Gaithersburg, MD 20878, USA. harperja@medimmune.com., Wu H; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA. wuh@medimmune.com., Howard PW; Spirogen Inc., London, E1 2AX, UK. howardp@medimmune.com., Gao C; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA. gaoc@medimmune.com.
Publikováno v:
Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2017 Nov 28; Vol. 6 (4). Date of Electronic Publication: 2017 Nov 28.
Autor:
Kemp GC; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., Tiberghien AC; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK. Electronic address: tiberghiena@medimmune.com., Patel NV; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., D'Hooge F; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., Nilapwar SM; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., Adams LR; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., Corbett S; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., Williams DG; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., Hartley JA; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK., Howard PW; Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, UK. Electronic address: Philip.Howard@spirogen.com.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2017 Mar 01; Vol. 27 (5), pp. 1154-1158. Date of Electronic Publication: 2017 Jan 30.
Autor:
Tiberghien AC; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Levy JN; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Masterson LA; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Patel NV; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Adams LR; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Corbett S; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Williams DG; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Hartley JA; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K., Howard PW; QMB Innovation Centre, Spirogen , 42 New Road, E1 2AX London, U.K.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2016 May 24; Vol. 7 (11), pp. 983-987. Date of Electronic Publication: 2016 May 24 (Print Publication: 2016).
Autor:
Jeffrey SC; Department of Research & Translational Medicine, Seattle Genetics, Inc., Bothell, WA 98021, USA. sjeffrey@seagen.com, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law CL, Senter PD
Publikováno v:
Bioconjugate chemistry [Bioconjug Chem] 2013 Jul 17; Vol. 24 (7), pp. 1256-63. Date of Electronic Publication: 2013 Jun 28.
Autor:
Hartley JA; Spirogen Ltd., UCL Cancer Institute, UK. john.hartley@ucl.ac.uk., Hamaguchi A, Coffils M, Martin CR, Suggitt M, Chen Z, Gregson SJ, Masterson LA, Tiberghien AC, Hartley JM, Pepper C, Lin TT, Fegan C, Thurston DE, Howard PW
Publikováno v:
Cancer research [Cancer Res] 2010 Sep 01; Vol. 70 (17), pp. 6849-58. Date of Electronic Publication: 2010 Jul 26.